Sanofi India Limited has informed the Exchange regarding outcome of the Board Meeting of the Company held on Wednesday, 14th May 2025

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹6054.50

prior close

₹6200.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+3.2% vs market

Pharmaceuticals peers, median of 150sector+0.4%+3.9% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.4

15m

-0.0

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+1.0+3.2+0.4+3.9

Next day

+3.9+1.8+2.1+0.8+3.1

+3.2+3.0+0.2+1.8+1.4

+3.7+1.9+1.8+1.1+2.5

+5.3+2.7+2.6+1.9+3.4

+3.6+2.6+1.0+1.8+1.7

+3.7+3.8-0.1+1.7+2.1

15d

+1.7+5.7-3.9+2.8-1.0

+1.4+6.7-5.2+2.9-1.5

-1.4+9.6-11.0+4.8-6.2

-15.8+4.6-20.3+0.2-15.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India's Board approved its Q1 2025 unaudited financial results on May 14, 2025. Net sales grew 4% year-on-year on a comparable basis (continuing business), driven by the steady ramp-up of its diabetes drug Soliqua®. Revenue from operations rose to ₹5,359 million from ₹5,108 million in Q1 2024. Operating profit jumped 27% to ₹1,653 million (vs ₹1,312 million), helped by lower total expenses of ₹3,739 million (down from ₹3,831 million). Profit from continuing operations surged to ₹1,195 million from ₹720 million, translating to EPS of ₹51.89 (vs ₹31.26). Note: Q1 2024 figures were impacted by an exceptional personnel separation cost of ₹267 million, and the Consumer Healthcare business has been classified as discontinued operations following its June 2024 demerger.

Likely market impact

Positive quarter for shareholders — strong double-digit growth in operating profit and EPS signals improving cost efficiency and pricing power in the core pharma business. The optics are partly aided by a low base (exceptional cost in Q1 2024) and the demerger of Consumer Healthcare, so underlying momentum should be assessed on the continuing-business basis.